Aduro BioTech, Inc. announces a collaboration with Charles G. Drake, M.D., Ph.D., Associate Professor of Oncology, Immunology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center to evaluate the therapeutic approach of anti-PD-1 in combination with one or both of Aduroâ€™s vaccine technologies based on live, attenuated Listeria monocytogenes and STING-activating adjuvants. The collaboration will be supported in part by a recent grant award from the Melanoma Research Foundation to Dr. Drake.
â€œWe are already on the cutting edge of combination immunotherapy for cancer and adding anti-PD-1 provides the potential for additional synergy and efficacy.â€
Blockade of PD-1 by a monoclonal antibody has shown promising efficacy in several Phase 1 trials in multiple cancers, including melanoma. The collaboration and grant are based on the hypothesis that anti-PD-1 may be synergistic in combination with one or more of Aduroâ€™s vaccine technologies for treating melanoma.
â€œWe are excited to be collaborating with Dr. Drake and to be expanding our vaccine approaches for melanoma,â€ said Thomas W. Dubensky, Jr., Ph.D., chief scientific officer at Aduro. â€œWe are already on the cutting edge of combination immunotherapy for cancer and adding anti-PD-1 provides the potential for additional synergy and efficacy.â€
SOURCE Aduro BioTech, Inc.